Belite Bio, Inc (BLTE)
NEGATIVEFundamental
~26
मूल्य
$162.31
मार्केट कैप
$6.44B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
सीमित वित्तीय डेटा उपलब्ध है (33% मेट्रिक्स)। स्कोर इस कंपनी के fundamentals को सटीक रूप से प्रतिबिंबित नहीं कर सकते।
बैलेंस शीट और तरलता
राजस्व
0
31/12/2025 को समाप्त वित्त वर्ष
शुद्ध आय
$-78M
31/12/2025 को समाप्त वित्त वर्ष
Free Cash Flow
-
कुल इक्विटी
$777M
कुल देनदारियाँ
0
Current Ratio
33.56
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$214.00
वर्तमान मूल्य
$162.31
Margin of Safety
+24.2%
Fair Value सीमा
$203.30 - $224.70
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-22.1%
P/B Ratio
8.11
P/FCF
-
Gross Margin
0.0%
ROIC
-
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Fundamental विश्लेषण मानदंड
पास (3)
- Price CAGR 52.03%
- Current Ratio
- Analyst Consensus 93% Buy
फेल (6)
- Gross Margin 0.0%
- P/B Ratio 8.11
- DCF valuation (Unknown)
- ROE -26.9%
- Earnings Surprise avg -19.7%
- Piotroski F-Score 0/9
अनुपलब्ध (18)
- EPS data insufficient
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | 47 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | 41 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 59 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 56 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for BLTE, sourced from Markets Gazette.
- 3/3/2026NEUTRALBelite Bio (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio (BLTE) investors are awaiting crucial details following the announcement of the Q4 2025 earnings call transcript. Although the event was reported, the actual content of the transcript is not yet available. This lack of information prevents analysts and investors from assessing the company's financial performance, future outlook, or any significant announcements that could impact the stock's value. Transparency is key for the market, and the absence of concrete data keeps the stock in a phase of uncertainty, with operators eagerly awaiting details to formulate forecasts and make informed decisions.
via Markets Gazette